Kamada (KMDA) investor relations material

Executive summary

• Q1 2026 operational and financial performance was solid, with net income of $4.1 million (up 4% YoY), despite a temporary shipment delay that impacted reported results but was resolved in April.

• Underlying demand for products remains strong, supporting confidence in significantly stronger results for the remainder of 2026.

• Focus remains on a four-pillar growth strategy: organic growth, distribution expansion, plasma collection, and business development/M&A.

• Ongoing evaluation of business development and M&A opportunities to enhance long-term growth.

• Expansion of the commercial portfolio, including biosimilars and plasma collection, is a key priority.

Financial highlights

• Q1 2026 revenues were reported as $42.5 million (down 3% YoY) and $45.2 million (up 3% YoY), with the difference attributed to a $2.4 million shipment delay.

• Gross profit was $19.1 million with a gross margin of 42%, down from 47% in Q1 2025, reflecting product and market sales mix.

• Operating expenses totaled $12.1 million, down from $13 million in Q1 2025, mainly due to lower R&D after InnovAATe trial termination.

• Net income was $4.1 million ($0.07 per diluted share), up 4% from Q1 2025.

• Adjusted EBITDA was $11.6 million (26% margin), unchanged from Q1 2025.

Outlook and guidance

• 2026 annual guidance reiterated: revenues of $200–$205 million and adjusted EBITDA of $50–$53 million, representing 12% and 23% growth over 2025 midpoints.

• Guidance is based solely on organic growth, with additional upside potential from business development and M&A.

• Expectation for a significantly stronger performance in the remainder of 2026, driven by increasing demand and operational expansion.